Dr. Chris Parker: Abiraterone Will Change Practice in Advanced Prostate Cancer
Dr. Chris Parker: Abiraterone Will Change Practice in Advanced Prostate Cancer
Interview by L Scott Zoeller
20110004
2011 Jan 4
Top Stories of 2010
Dr. Chris Parker: Abiraterone Will Change Practice in Advanced Prostate Cancer
Top Stories of 2010. 2011 Jan 4, Interview by L Scott Zoeller
Abstract
Dr. Chris Parker is Honorary Consultant in Clinical Oncology at the Royal Marsden Hospital and Senior Lecturer in Prostate Cancer Translational Research at the Institute of Cancer Research, Sutton, United Kingdom. OncologySTAT: In your view, which development in prostate cancer research that occurred in 2010 could have the most significant impact on oncology?Dr. Parker: Abiraterone in advanced prostate cancer. Abiraterone is a novel agent that inhibits the biosynthesis of testosterone. It dramatically...
Meet Our Experts
Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.
